Predictive biomarkers for drug response in bladder cancer

Mouse and human urothelial cancer organoids: A tool for bladder cancer research

(2019) Jasper Mullenders et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability

(2019) Jaegil Kim et al.   EUROPEAN UROLOGY

Cancer statistics, 2018

(2018) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA

(2018) Neeraj Agarwal et al.   CANCER

Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer

(2018) Suk Hyung Lee et al.   CELL

ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer

(2018) Qiang Li et al.   CLINICAL CANCER RESEARCH

An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers

(2018) Mélanie Mahe et al.   EMBO Molecular Medicine

Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis

(2018) Karin Birkenkamp-Demtröder et al.   EUROPEAN UROLOGY

Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications

(2018) Daniel H. Hovelson et al.   EUROPEAN UROLOGY

Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer

(2018) Gopa Iyer et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

(2018) Thomas Powles et al.   LANCET

Discordant molecular subtype classification in the basal-squamous subtype of bladder tumors and matched lymph-node metastases

(2018) Gottfrid Sjödahl et al.   MODERN PATHOLOGY

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

(2018) Georgios Vlachogiannis et al.   SCIENCE

Detection and localization of surgically resectable cancers with a multi-analyte blood test

(2018) Joshua D. Cohen et al.   SCIENCE

Characterization of Urothelial Cancer Circulating Tumor Cells with a Novel Selection-Free Method

(2018) Heather J. Chalfin et al.   UROLOGY

Three-dimensional organoid culture reveals involvement of Wnt/β-catenin pathway in proliferation of bladder cancer cells

(2018) Takahiro Yoshida et al.   Oncotarget

Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy

(2018) Simeon U Springer et al.   eLife

Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy

(2018) Zhao Yang et al.   EBioMedicine

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer

(2018) A. Gordon Robertson et al.   CELL

Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors

(2018) Tuan Zea Tan et al.   EUROPEAN UROLOGY

Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants

(2018) Joshua I. Warrick et al.   EUROPEAN UROLOGY

Genomic Differences Between “Primary” and “Secondary” Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy

(2018) Eugene J. Pietzak et al.   EUROPEAN UROLOGY

Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends

(2017) Sebastien Antoni et al.   EUROPEAN UROLOGY

Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy

(2017) Roland Seiler et al.   EUROPEAN UROLOGY

Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification

(2017) Gottfrid Sjödahl et al.   JOURNAL OF PATHOLOGY

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

(2017) Padmanee Sharma et al.   LANCET ONCOLOGY

Landmarks in the treatment of muscle-invasive bladder cancer

(2017) Niyati Lobo et al.   Nature Reviews Urology

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

(2017) Joaquim Bellmunt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intravesical BCG Induces CD4 + T-Cell Expansion in an Immune Competent Model of Bladder Cancer

(2017) Max Kates et al.   Cancer Immunology Research

Bladder cancer

(2017) Oner Sanli et al.   Nature Reviews Disease Primers

Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy

(2017) Bernhard Kiss et al.   Scientific Reports

Tumor heterogeneity offibroblast growth factor receptor 3(FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment

(2016) D. Pouessel et al.   ANNALS OF ONCOLOGY

Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin

(2016) Ashish M. Kamat et al.   EUROPEAN UROLOGY

ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy

(2016) Floris H. Groenendijk et al.   EUROPEAN UROLOGY

A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer

(2016) David J. McConkey et al.   EUROPEAN UROLOGY

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Bladder cancer

(2016) Ashish M Kamat et al.   LANCET

Systemic, perioperative management of muscle-invasive bladder cancer and future horizons

(2016) Samuel A. Funt et al.   Nature Reviews Clinical Oncology

Clinical Validation of Chemotherapy Response BiomarkerERCC2in Muscle-Invasive Urothelial Bladder Carcinoma

(2016) David Liu et al.   JAMA Oncology

Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use

(2016) Vipulkumar Dadhania et al.   EBioMedicine

Genetic subtypes of invasive bladder cancer

(2015) David J. McConkey et al.   CURRENT OPINION IN UROLOGY

Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer

(2015) Elizabeth R. Plimack et al.   EUROPEAN UROLOGY

Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer

(2015) Tetsutaro Hayashi et al.   JOURNAL OF UROLOGY

Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy

(2014) Woonyoung Choi et al.   CANCER CELL

The burden of bladder cancer care

(2014) Matthew Mossanen et al.   CURRENT OPINION IN UROLOGY

Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Is Safe, Effective, and Efficient Neoadjuvant Treatment for Muscle-Invasive Bladder Cancer: Results of a Multicenter Phase II Study With Molecular Correlates of Response and Toxicity

(2014) Elizabeth R. Plimack et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive molecular characterization of urothelial bladder carcinoma

(2014)   NATURE

Discovery and saturation analysis of cancer genes across 21 tumour types

(2014) Michael S. Lawrence et al.   NATURE

Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology

(2014) J. S. Damrauer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma

(2014) E. M. Van Allen et al.   Cancer Discovery

Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib

(2014) N. Wagle et al.   Cancer Discovery

Bacillus Calmette-Guérin immunotherapy for genitourinary cancer

(2013) Nilay M. Gandhi et al.   BJU INTERNATIONAL

Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder

(2013) E Xylinas et al.   BRITISH JOURNAL OF CANCER

A High Frequency of Activating Extracellular Domain ERBB2 (HER2) Mutation in Micropapillary Urothelial Carcinoma

(2013) J. S. Ross et al.   CLINICAL CANCER RESEARCH

A Molecular Taxonomy for Urothelial Carcinoma

(2012) G. Sjodahl et al.   CLINICAL CANCER RESEARCH

Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2

(2012) H. Greulich et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Genome Sequencing Identifies a Basis for Everolimus Sensitivity

(2012) G. Iyer et al.   SCIENCE

Preexisting BCG-Specific T Cells Improve Intravesical Immunotherapy for Bladder Cancer

(2012) C. Biot et al.   Science Translational Medicine

Markers Predicting Response to Bacillus Calmette-Guérin Immunotherapy in High-Risk Bladder Cancer Patients: A Systematic Review

(2011) Tahlita C.M. Zuiverloon et al.   EUROPEAN UROLOGY

Practical implications of gene-expression-based assays for breast oncologists

(2011) Aleix Prat et al.   Nature Reviews Clinical Oncology

FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy

(2010) Lucie C. Kompier et al.   PLoS One

Recurrence and Progression of Disease in Non–Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy

(2009) Bas W.G. van Rhijn et al.   EUROPEAN UROLOGY

Economic aspects of bladder cancer: what are the benefits and costs?

(2009) K. D. Sievert et al.   WORLD JOURNAL OF UROLOGY